Actualités

Iovance Biotherapeutics (IOVA) is back in focus after Australia’s Therapeutic Goods Administration granted conditional approval for Amtagvi, a tumor infiltrating lymphocyte therapy for previously treated unresectable or metastatic melanoma in a high incidence market. See our latest analysis for Iovance Biotherapeutics. The TGA decision comes after a volatile period, with the stock delivering a 67.86% year to date share price return and a 106.34% total shareholder return over one year...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 8, Chardan reiterated Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) as a Buy but lowered its price target of the stock to $14 from $16. The price target cut is in response to Amtagvi’s launch guidance. The company delivered […]

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 9 Stocks Crushing the Market With Surging Returns. Iovance Biotherapeutics climbed by 15.57 percent on Thursday to end at $4.38 apiece after securing the conditional approval of Australia’s Therapeutic Goods Administration (TGA) for the treatment of melanoma through its therapy, Amtagvi. The approval marked Iovance Biotherapeutics Inc.’s (NASDAQ:IOVA) […]

Tread carefully, but certain factors make this speculative biotech play stand out.

Iovance Biotherapeutics recently received FDA clearance to proceed with an investigational new drug application for IOV-5001, a next-generation IL-12 tethered tumor infiltrating lymphocyte therapy, enabling a Phase 1/2 trial in advanced colorectal, triple-negative, estrogen receptor-low breast cancers and other solid tumors. The therapy’s design to localize IL-12 expression within tumors, by tethering it to TIL cell surfaces, highlights Iovance’s push to refine efficacy while aiming to limit...

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

Stock move puts Iovance Biotherapeutics (IOVA) back in focus Iovance Biotherapeutics (IOVA) has drawn attention after recent trading, with the stock closing at $4.11 and posting double-digit total returns over the past month and the past three months. See our latest analysis for Iovance Biotherapeutics. The recent 1-day share price return of 11.08% and 7-day share price return of 19.13%, on top of a 63.10% year to date share price return, point to building momentum, although the 3-year total...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 7, 2026, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported Q1 EPS of (19c), versus the consensus estimate of (15c). Revenue totaled $71.43M, versus the consensus estimate of $75.66M. Interim President and Chief Executive Officer Frederick Vogt said the […]

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, Chardan reduced its price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) from $16 to $14 while maintaining a Buy rating on the stock. This update comes after the company’s first-quarter 2026 results. Chardan’s analyst told investors in […]

Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) just released its latest quarterly report and things are not looking...

Iovance Biotherapeutics reported past first-quarter 2026 results with revenue rising to US$71.43 million while net loss narrowed to US$79.05 million, alongside a proposal to lift authorized common shares to 650,000,000. Management highlighted AMTAGVI-driven growth and strengthened guidance supported by improving gross margins and encouraging early data in metastatic serous endometrial cancer, signaling operational and pipeline momentum. Now we’ll examine how this AMTAGVI-fueled revenue jump...

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

Iovance Biotherapeutics (NASDAQ:IOVA) reported first-quarter 2026 revenue of $71 million, up roughly 45% year-over-year, as the company pointed to rising demand for its tumor-infiltrating lymphocyte (TIL) therapy AMTAGVI and expanding commercial execution. Management also reiterated that recent manu

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6%

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Iovance Biotherapeutics Stock Is Back on Investors’ Radar Iovance Biotherapeutics (IOVA) is drawing fresh attention after short interest in the stock eased and several large institutions increased positions, hinting at a shift in how the market is approaching the company. This interest arrives alongside a proposal for the June 10, 2026 annual meeting to raise authorized common shares from 500,000,000 to 650,000,000. This is a move that can affect how you think about future financing and...

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.96% and -15.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

It could just as well drop by 50% -- or more -- over the next 12 months.

Pacira (PCRX) delivered earnings and revenue surprises of -1.64% and +0.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Iovance Biotherapeutics, listed as NasdaqGM:IOVA, has proposed a significant increase to its authorized common stock. Shareholders are scheduled to vote on the proposal at the company’s upcoming annual meeting. The authorization change would give the company more flexibility for future equity issuances, subject to board approval. Iovance Biotherapeutics focuses on cell therapies targeting cancer, an area that often requires substantial capital for clinical development, manufacturing...

Regeneron (REGN) delivered earnings and revenue surprises of +11.18% and +4.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?